Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL926371 | 0.98 | TKT (0.44) | TKTHSP90AA1 | |
| SCHEMBL8987960 | 0.84 | TKT (0.40) | TKTHSP90AA1 | |
| SCHEMBL9470885 | 0.81 | HTT (0.40) | TKT | |
| SCHEMBL3961010 | 0.78 | TKT (0.46) | TKTHSP90AA1 | |
| Bromide SCHEMBL8941023 | 0.76 | TKT (0.54) | TKTHSP90AA1 | |
| SCHEMBL2026240 | 0.76 | TKT (0.54) | TKTHSP90AA1 | |
| Bromide SCHEMBL3847375 | 0.76 | TKT (0.44) | TKTHSP90AA1 | |
| SCHEMBL16978264 | 0.75 | HSP90AA1 (0.43) | TKTHSP90AA1 | |
| Iodide SCHEMBL1779438 | 0.75 | TKT (0.52) | TKTHSP90AA1 | |
| Bromide SCHEMBL447562 | 0.75 | TKT (0.52) | TKTHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0808163-B1 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC (US) | 2003-07-23 | — | — | EP | claimed |
| US-6440749-B1 | ADMINISTERING A THIAZOLE COMPOUND | ALTEON. INC. | 2002-08-27 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0615854-B1 | Recording sheets containing cationic sulphur compounds | XEROX CORP (US) | 1997-06-04 | — | — | EP | claimed |
| EP-0330172-B1 | Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis | WARNER LAMBERT CO (US) | 1994-08-10 | — | — | EP | claimed |
| EP-0244717-A2 | Process for the preparation of 2,3-epoxyamides | BAYER AG (DE) | 1987-11-11 | — | — | EP | claimed |
| US-20220018826-A1 | COLORIMETRIC PLASMONIC NANOSENSOR FOR DOSIMETRY OF THERAPEUTIC LEVELS OF IONIZING RADIATION | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-01-20 | — | — | US | disclosed |
| EP-3267963-A1 | POLYMERIZABLE DENTAL MATERIAL HAVING A PHASE TRANSFER CATALYST | Kettenbach GmbH & CO. KG (DE) | 2018-01-17 | — | — | EP | disclosed |
| US-20170327449-A1 | NOVEL PROCESS FOR PREPARING SYNTHESIS INTERMEDIATES USING PRODUCTS OF NATURAL ORIGIN AND USE OF THE INTERMEDIATES OBTAINED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-11-16 | — | — | US | disclosed |
| EP-2739614-B1 | AMINOCHROMANEs, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2017-02-22 | — | — | EP | disclosed |
| WO-2016142296-A1 | POLYMERIZABLE DENTAL MATERIAL HAVING A PHASE TRANSFER CATALYST | KETTENBACH GMBH & CO. KG (DE) | 2016-09-15 | — | — | WO | disclosed |
| US-8853196-B2 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-07 | — | — | US | disclosed |
| US-20130035323-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2013-02-07 | — | — | US | disclosed |
| WO-2012170494-A1 | NON-ENZYMATIC SYNTHESIS OF O-ACETYL-ADP-RIBOSE AND ANALOGUES THEREOF | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | PFIZER INC | 2012-06-21 | — | — | US | disclosed |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | PFIZER INC | 2011-04-28 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| EP-0284395-A2 | Novel glycerol derivative and anti-hypertensive agent | NIPPON CHEMIPHAR CO., LTD. (JP) | 1988-09-28 | — | — | EP | disclosed |
| EP-0244717-A2 | Process for the preparation of 2,3-epoxyamides | BAYER AG (DE) | 1987-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035323-A1 | AMINOCHROMANE, AMINOTHIOCHROMANE AND AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC7A1, BCAT1, AADAT | TKT 318/4885HSP90AA1 2717/4885 |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PDE5A, PDE3B, PDE12 | TKT 1164/4885HSP90AA1 3744/4885 |
| US-20120157440-A1 | NOVEL FUSED PYRIDINE COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK1A1, CSNK1A1L, CSNK1E | TKT 1988/4885HSP90AA1 3927/4885 |
| US-20170327449-A1 | NOVEL PROCESS FOR PREPARING SYNTHESIS INTERMEDIATES USING PRODUCTS OF NATURAL ORIGIN AND USE OF THE INTERMEDIATES OBTAINED | ADH7, ADH1B, ADH4 | TKT 25/4885HSP90AA1 1258/4885 |
| US-20110098272-A1 | Novel Compounds As Casein Kinase Inhibitors | CSNK1A1, CSNK1A1L, CSNK1G1 | TKT 641/4885HSP90AA1 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.